$MRZM
Marizyme Inc Stock $mrzm

$mrzm Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000149315223017299 Filed on May 15, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$184.7K	$129.0K
YoY Change	198.89%
Cost Of Revenue	$49.61K	$39.28K
YoY Change	349.78%
Gross Profit	$135.1K	$89.70K
YoY Change	166.1%
Gross Profit Margin	73.15%	69.55%
Selling, General & Admin	$3.875M	$1.370M	$2.567M
YoY Change	26.2%	-46.62%	13.82%
% of Gross Profit	2867.92%	1527.4%
Research & Development	$691.4K	$606.0K	$1.218M
YoY Change	-49.59%	-50.26%
% of Gross Profit	511.66%	675.59%
Depreciation & Amortization	$210.3K	$210.3K	$210.4K
YoY Change	-0.03%	-0.01%	-49.5%
% of Gross Profit	155.62%	234.49%
Operating Expenses	$4.939M	$2.223M	$3.995M
YoY Change	5.91%	-44.37%	77.18%
Operating Profit	-$4.804M	-$2.133M	-$3.995M
YoY Change	4.39%	-46.62%	80.63%
Interest Expense	-$13.42M	-$1.698M	-$299.5K
YoY Change	2431.76%	466.77%
% of Operating Profit
Other Income/Expense, Net	-$15.77M	-$421.7K	-$1.830M
YoY Change	579.19%	-76.96%
Pretax Income	-$20.58M	-$2.555M	-$6.125M
YoY Change	197.18%	-58.29%	176.91%
Income Tax
% Of Pretax Income
Net Earnings	-$20.58M	-$2.555M	-$6.125M
YoY Change	197.18%	-58.29%	176.91%
Net Earnings / Revenue	-11138.09%	-1980.7%
Basic Earnings Per Share	-$0.48	-$0.06	-$0.15
Diluted Earnings Per Share	-$0.48	-$0.06	-$150.8K
COMMON SHARES
Basic Shares Outstanding	43.42M shares	40.77M shares	40.63M shares
Diluted Shares Outstanding	43.19M shares	40.76M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$205.2K	$329.8K	$3.173M
YoY Change	-89.96%	-89.61%	280.01%
Cash & Equivalents	$205.2K	$329.8K	$3.173M
Short-Term Investments
Other Short-Term Assets	$606.4K	$1.259M	$469.9K
YoY Change	157.6%	167.97%	644.71%
Inventory	$139.7K	$176.5K	$15.54K
Prepaid Expenses	$606.3K	$1.259M
Receivables	$72.98K	$78.17K	$8.650K
Other Receivables	$34.30K	$35.23K	$20.81K
Total Short-Term Assets	$1.059M	$1.879M	$3.688M
YoY Change	-59.51%	-49.05%	276.9%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.50K	$12.50K	$1.111M
YoY Change	-1.43%	-98.87%	-11.98%
Goodwill	$7.191M	$7.191M
YoY Change	0.0%
Intangibles		$27.46M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$170.8K	$332.9K	$369.1K
YoY Change	-53.71%	-9.8%	-0.51%
Total Long-Term Assets	$35.92M	$36.39M	$61.33M
YoY Change	-41.76%	-40.66%	40.79%
TOTAL ASSETS
Total Short-Term Assets	$1.059M	$1.879M	$3.688M
Total Long-Term Assets	$35.92M	$36.39M	$61.33M
Total Assets	$36.98M	$38.27M	$65.01M
YoY Change	-42.49%	-41.14%	45.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.038M	$1.873M	$822.6K
YoY Change	230.29%	127.71%	84.82%
Accrued Expenses	$428.8K	$426.1K	$277.1K
YoY Change	2.5%	53.76%	-8.87%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$284.9K
YoY Change	-100.0%	-100.0%
Long-Term Debt Due	$12.75M	$5.639M
YoY Change	5181.86%
Total Short-Term Liabilities	$20.82M	$8.027M	$1.656M
YoY Change	1287.72%	384.72%	121.04%
LONG-TERM LIABILITIES
Long-Term Debt	$307.4K	$792.2K	$318.1K
YoY Change	-63.53%	149.08%
Other Long-Term Liabilities	$8.583M	$14.22M	$17.79M
YoY Change	-58.35%	-20.05%	1718.28%
Total Long-Term Liabilities	$8.890M	$15.01M	$18.10M
YoY Change	-58.56%	-17.08%	1750.79%
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.82M	$8.027M	$1.656M
Total Long-Term Liabilities	$8.890M	$15.01M	$18.10M
Total Liabilities	$29.71M	$23.04M	$19.76M
YoY Change	29.46%	16.59%	1043.93%
SHAREHOLDERS EQUITY
Retained Earnings	-$109.1M	-$88.54M
YoY Change	79.26%
Common Stock	$45.37K	$40.77K
YoY Change	11.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$7.270M	$15.23M	$45.25M
YoY Change
Total Liabilities & Shareholders Equity	$36.98M	$38.27M	$65.01M
YoY Change	-42.49%	-41.14%	45.97%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$20.58M	-$2.555M	-$6.125M
YoY Change	197.18%	-58.29%	176.91%
Depreciation, Depletion And Amortization	$210.3K	$210.3K	$210.4K
YoY Change	-0.03%	-0.01%	-49.5%
Cash From Operating Activities	-$1.198M	-$1.120M	-$4.314M
YoY Change	-56.31%	-74.03%	108.89%
INVESTING ACTIVITIES
Capital Expenditures			$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.073M	$939.1K	3.414M
YoY Change	-33.5%	-72.5%
NET CHANGE
Cash From Operating Activities	-1.198M	-$1.120M	-4.314M
Cash From Investing Activities
Cash From Financing Activities	1.073M	$939.1K	3.414M
Net Change In Cash	-124.6K	-$181.1K	$0.00
YoY Change	-88.96%
FREE CASH FLOW
Cash From Operating Activities	-$1.198M	-$1.120M	-$4.314M
Capital Expenditures			$0.00
Free Cash Flow			-$4.314M
YoY Change			109.18%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001413754
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent		usd
CY2023Q1	us-gaap	Other Liability Current Related And Nonrelated Party Status Extensible Enumeration OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q4	us-gaap	Other Liability Current Related And Nonrelated Party Status Extensible Enumeration OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2022Q1	us-gaap	Gross Profit GrossProfit		usd
CY2022Q1	us-gaap	Royalty Expense RoyaltyExpense		usd
CY2023Q1	MRZM	Issuance Of Warrants For Services IssuanceOfWarrantsForServices		usd
CY2022Q1	us-gaap	Litigation Settlement Expense LitigationSettlementExpense		usd
CY2023Q1	MRZM	Proceeds From Financing Net Of Issuance Cost ProceedsFromFinancingNetOfIssuanceCost		usd
CY2023Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2022Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q1	MRZM	Derivative Liabilities And Debt Discount Issued In Connection With Convertible Notes DerivativeLiabilitiesAndDebtDiscountIssuedInConnectionWithConvertibleNotes		usd
CY2023Q1	MRZM	Warrants And Debt Discount Issued In Connection With Convertible Notes WarrantsAndDebtDiscountIssuedInConnectionWithConvertibleNotes		usd
CY2023Q1	MRZM	Settlement Of Notes Payable With Convertible Notes SettlementOfNotesPayableWithConvertibleNotes		usd
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2023Q1	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold		usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent		usd
CY2023Q1	us-gaap	Other Liability Current Related And Nonrelated Party Status Extensible Enumeration OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q4	us-gaap	Other Liability Current Related And Nonrelated Party Status Extensible Enumeration OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q1	us-gaap	Operating Cost And Expense Related And Nonrelated Party Status Extensible Enumeration OperatingCostAndExpenseRelatedAndNonrelatedPartyStatusExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q1	us-gaap	Operating Cost And Expense Related And Nonrelated Party Status Extensible Enumeration OperatingCostAndExpenseRelatedAndNonrelatedPartyStatusExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	000-53223
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	MARIZYME, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-5464863
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	555 Heritage Drive
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 205
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Jupiter
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33458
CY2023Q1	dei	City Area Code CityAreaCode	(561)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	935-9955
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	43420350	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	329805	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	510865	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	78169	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	87801	usd
CY2023Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	35226	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	15310	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1259230	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1125761	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	176527	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	215566	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	1878957	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1955303	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12500	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12545	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1390042	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1485023	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	27464727	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	27675020	usd
CY2023Q1	MRZM	Prepaid Royalties Noncurrent PrepaidRoyaltiesNoncurrent	302908	usd
CY2022Q4	MRZM	Prepaid Royalties Noncurrent PrepaidRoyaltiesNoncurrent	339091	usd
CY2023Q1	us-gaap	Deposit Assets DepositAssets	30000	usd
CY2022Q4	us-gaap	Deposit Assets DepositAssets	30000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	7190656	usd
CY2022Q4	us-gaap	Goodwill Goodwill	7190656	usd
CY2023Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	36390833	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	36732335	usd
CY2023Q1	us-gaap	Assets Assets	38269790	usd
CY2022Q4	us-gaap	Assets Assets	38687638	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1873019	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1365443	usd
CY2023Q1	us-gaap	Notes Payable Current NotesPayableCurrent	2123211	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	1132829	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	89016	usd
CY2023Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	3515600	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	426142	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	423495	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	8026988	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2921767	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	963900	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1061528	usd
CY2023Q1	MRZM	Convertible Long Term Note Payable ConvertibleLongTermNotePayable	792210	usd
CY2022Q4	MRZM	Convertible Long Term Note Payable ConvertibleLongTermNotePayable	2751633	usd
CY2023Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	4823725	usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	4823725	usd
CY2023Q1	MRZM	Contingent Liabilities ContingentLiabilities	8431000	usd
CY2022Q4	MRZM	Contingent Liabilities ContingentLiabilities	9707000	usd
CY2023Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	15010835	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	18343886	usd
CY2023Q1	us-gaap	Liabilities Liabilities	23037823	usd
CY2022Q4	us-gaap	Liabilities Liabilities	21265653	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40768191	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40768191	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40528191	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40528191	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	40768	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	40528	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	103735216	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	103370890	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-88544017	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-85989433	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	15231967	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	17421985	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	38269790	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	38687638	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	128974	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	39275	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	89699	usd
CY2023Q1	us-gaap	Professional Fees ProfessionalFees	384806	usd
CY2022Q1	us-gaap	Professional Fees ProfessionalFees	544040	usd
CY2023Q1	us-gaap	Salaries And Wages SalariesAndWages	266968	usd
CY2022Q1	us-gaap	Salaries And Wages SalariesAndWages	915640	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	605997	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1218296	usd
CY2023Q1	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	210966	usd
CY2022Q1	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	716432	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	210338	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	210361	usd
CY2023Q1	us-gaap	Royalty Expense RoyaltyExpense	36183	usd
CY2023Q1	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	507324	usd
CY2022Q1	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	390572	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	2222582	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	3995341	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2132883	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3995341	usd
CY2023Q1	MRZM	Interest And Accretion Expenses Other InterestAndAccretionExpensesOther	1697701	usd
CY2022Q1	MRZM	Interest And Accretion Expenses Other InterestAndAccretionExpensesOther	299544	usd
CY2023Q1	MRZM	Gain Loss On Fair Value Of Contingent Liabilities GainLossOnFairValueOfContingentLiabilities	1276000	usd
CY2022Q1	MRZM	Gain Loss On Fair Value Of Contingent Liabilities GainLossOnFairValueOfContingentLiabilities	-1830000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-421701	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2129544	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2554584	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-6124885	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40757524	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40628188	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	47690332	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	716432	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	2969916	usd
CY2022Q1	MRZM	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	3000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-6124885	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	45254795	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	45254795	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	17421985	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	17421985	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	210966	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	153600	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2554584	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	15231967	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	15231967	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2554584	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-6124885	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	210338	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	210361	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	210966	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	716432	usd
CY2023Q1	MRZM	Interest And Accretion Expenses InterestAndAccretionExpenses	1697701	usd
CY2022Q1	MRZM	Interest And Accretion Expenses InterestAndAccretionExpenses	299544	usd
CY2022Q1	MRZM	Issuance Of Warrants For Services IssuanceOfWarrantsForServices	-568679	usd
CY2023Q1	MRZM	Gain Loss On Fair Value Of Contingent Liabilities GainLossOnFairValueOfContingentLiabilities	1276000	usd
CY2022Q1	MRZM	Gain Loss On Fair Value Of Contingent Liabilities GainLossOnFairValueOfContingentLiabilities	-1830000	usd
CY2023Q1	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	153600	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	10284	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-20501	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	133469	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	212744	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-39039	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-6818	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	453521	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-767187	usd
CY2023Q1	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	89016	usd
CY2022Q1	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-861263	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1120156	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4313744	usd
CY2022Q1	MRZM	Proceeds From Financing Net Of Issuance Cost ProceedsFromFinancingNetOfIssuanceCost	3411372	usd
CY2022Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3000	usd
CY2023Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	939096	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	939096	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3414372	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-181060	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-899372	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	510865	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4072339	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	329805	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3172967	usd
CY2022Q1	MRZM	Derivative Liabilities And Debt Discount Issued In Connection With Convertible Notes DerivativeLiabilitiesAndDebtDiscountIssuedInConnectionWithConvertibleNotes	1336218	usd
CY2022Q1	MRZM	Warrants And Debt Discount Issued In Connection With Convertible Notes WarrantsAndDebtDiscountIssuedInConnectionWithConvertibleNotes	2401237	usd
CY2022Q1	MRZM	Settlement Of Notes Payable With Convertible Notes SettlementOfNotesPayableWithConvertibleNotes	326083	usd
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023Q1	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2007-03-20
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-88544017	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-85989433	usd
CY2023Q1	MRZM	Working Capital WorkingCapital	6148031	usd
CY2022Q4	MRZM	Working Capital WorkingCapital	966464	usd
CY2023Q1	us-gaap	Cash Cash	329805	usd
CY2022Q4	us-gaap	Cash Cash	510865	usd
CY2023Q1	us-gaap	Deferred Offering Costs DeferredOfferingCosts	549795	usd
CY2022Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	387412	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84A_eus-gaap--UseOfEstimates_zwj1eWsrbfR6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zdcgZWHbabll">Use of Estimates</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the unaudited condensed consolidated financial statements in accordance with U.S. GAAP requires management to make use of certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the unaudited condensed consolidated financial statements and the reported amounts of revenue and expenses during the reported periods. The Company bases its estimates on historical experience and on various other assumptions that management believes are reasonable under the circumstances, the results of which form the basis for making judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. Significant estimates are related to the recoverability of long-term assets including intangible assets and goodwill, amortization expense, valuation of warrants, stock-based compensation, derivative liabilities and contingent liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	MRZM	Midrange Average Estimated Interest Rate MidrangeAverageEstimatedInterestRate	0.206	pure
CY2023Q1	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	667000	usd
CY2023Q1	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	4735000	usd
CY2022	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	5402000	usd
CY2020Q4	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	five-and-a-half-year lease agreement
CY2020Q4	us-gaap	Area Of Land AreaOfLand	10300	sqft
CY2022Q2	us-gaap	Area Of Land AreaOfLand	3053	sqft
CY2023Q1	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P3Y3M29D
CY2023Q1	us-gaap	Payments For Rent PaymentsForRent	154828	usd
CY2022Q1	us-gaap	Payments For Rent PaymentsForRent	110900	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1390042	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1485023	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	426142	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	423495	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	963900	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1061528	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1390042	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1485023	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	317621	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	434082	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	444934	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	266034	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1462671	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	72629	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1390042	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	29142745	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-1678018	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	27464727	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	53492745	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-1467725	usd
CY2022Q4	MRZM	Finite Lived Intangible Assets Impairment FiniteLivedIntangibleAssetsImpairment	-24350000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	27675020	usd
CY2023Q1	us-gaap	Goodwill Goodwill	7190656	usd
CY2021Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	52866192	usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	24350000	usd
CY2022	MRZM	Accumulated Amortization Of Intangible Assets AccumulatedAmortizationOfIntangibleAssets	841172	usd
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	27675020	usd
CY2023Q1	MRZM	Accumulated Amortization Of Intangible Assets AccumulatedAmortizationOfIntangibleAssets	210293	usd
CY2023Q1	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	27464727	usd
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40768191	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40768191	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40528191	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40528191	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	400000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3650943	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.24
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y4M2D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	400000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.20
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	62502	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	1.25
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	62498	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.25
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3925943	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.33
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y21D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3925943	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.33
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y9M21D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3336775	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.23
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y3M7D
CY2022Q1	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold	295750	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	210966	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	716432	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	89016	usd
CY2023Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	72000	usd
CY2022Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	60000	usd
CY2023Q1	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	7405	usd
CY2023Q1	us-gaap	Prepaid Royalties PrepaidRoyalties	302908	usd
CY2022Q4	us-gaap	Prepaid Royalties PrepaidRoyalties	339091	usd
CY2019Q3	MRZM	Royalties Percentage RoyaltiesPercentage	0.10	pure

Files In Submission

Name	View Source	Status
mrzm-20230331_pre.xml	Edgar Link	unprocessable
0001493152-23-017299-index-headers.html	Edgar Link	pending
0001493152-23-017299-index.html	Edgar Link	pending
0001493152-23-017299.txt	Edgar Link	pending
0001493152-23-017299-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
form10-q_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mrzm-20230331.xsd	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
mrzm-20230331_cal.xml	Edgar Link	unprocessable
mrzm-20230331_def.xml	Edgar Link	unprocessable
mrzm-20230331_lab.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MRZM
Marizyme Inc Stock $mrzm

2023 Q2 Form 10-Q Financial Statement

#000149315223017299 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRZM Marizyme Inc Stock $mrzm

2023 Q2 Form 10-Q Financial Statement

#000149315223017299 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRZM
Marizyme Inc Stock $mrzm